Mirum Pharmaceuticals Director Exercises 5,000 Options, Totaling $400,000 in Transactions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Fool
- Options Exercise and Sale: Mirum Pharmaceuticals director Saira Ramasastry exercised 5,000 stock options and immediately sold the shares in the open market for a total of $400,000, reflecting confidence in the company's future prospects.
- Shareholding Change: This transaction reduced Ramasastry's direct common stock holdings to zero, although she retains 10,000 options, preserving potential upside and indicating continued optimism about the company's outlook.
- Financial Performance: Preliminary results for Mirum Pharmaceuticals show net product sales of approximately $520 million for 2025, exceeding guidance, with management forecasting global net product sales of $630 million to $650 million for 2026, highlighting strong market demand.
- Cash Flow and Expansion Plans: The company ended 2025 with about $392 million in cash and investments, achieving positive operating cash flow, which provides flexibility to fund pipeline expansion and the upcoming acquisition of Bluejay Therapeutics.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like MIRM with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on MIRM
Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 102.33 USD with a low forecast of 81.00 USD and a high forecast of 140.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 100.850
Low
81.00
Averages
102.33
High
140.00
Current: 100.850
Low
81.00
Averages
102.33
High
140.00
About MIRM
Mirum Pharmaceuticals, Inc. is a rare disease company with a global footprint of approved products and a pipeline of investigational medicines. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirum Pharmaceuticals' Stock Doubles, Poised for Further Gains in 2026
- Positive Cash Flow: Mirum Pharmaceuticals achieved positive cash flow from operations in 2025, marking a significant milestone for a small biotech firm, which is expected to enhance investor confidence and drive stock price appreciation.
- FDA Drug Approvals: In 2025, Mirum received FDA approvals for Ctexli and Livmarli, targeting rare bile acid synthesis disorders and cholestatic pruritus, respectively, which are anticipated to significantly boost revenue and expand market share.
- Acquisition of Bluejay Therapeutics: On January 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics, adding the promising therapy brelovitug for chronic hepatitis delta virus to its pipeline, potentially providing strong momentum for future revenue growth.
- Clinical Trial Catalysts: Mirum is set to announce results from the Phase 2B trial of volixibat in Q2 2026, and if approved, it could fill a treatment gap for primary sclerosing cholangitis in the U.S., further propelling the company's stock price upward.
Continue Reading
Mirum Pharmaceuticals (MIRM) Price Target Raised to $102 Amid Strong 2026 Outlook
- Analyst Price Target Increase: Baird analyst Brian Skorney raised Mirum Pharmaceuticals' price target from $81 to $95 while maintaining an Outperform rating, reflecting the company's preliminary earnings results that exceeded expectations and demonstrated strong profitability and outlook.
- Positive Financial Outlook: H.C. Wainwright also raised its price target for Mirum from $81 to $102, maintaining a Buy rating, praising the company's impressive preliminary financial results and expressing optimism for 2026.
- Market Leadership: Citizens raised Mirum's price target from $95 to $140 on December 19, maintaining an Outperform rating, noting that Mirum has outperformed year-to-date and is expected to maintain its leadership position in 2026, driven by several high-confidence pivotal readouts in its clinical pipeline.
- Biopharmaceutical Prospects: Mirum Pharmaceuticals focuses on developing and commercializing novel therapies for debilitating rare diseases, and while there are other AI stocks with potential investment opportunities, its growth potential in the biopharmaceutical sector remains significant.
Continue Reading